Research programme: neurodegenerative disease therapeutics - ProteoTech

Drug Profile

Research programme: neurodegenerative disease therapeutics - ProteoTech

Alternative Names: DP-68; DP-74; PD 61 W3; PeptiClere; PTI-19; PTI-51; PTI-51-CH3; Synuclere; TauPro

Latest Information Update: 06 Apr 2015

Price : $50

At a glance

  • Originator ProteoTech
  • Class Carbohydrates; Peptides; Small molecules
  • Mechanism of Action Alpha-synuclein inhibitors; Amyloid beta-protein inhibitors; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Multiple system atrophy; Parkinson's disease; Progressive supranuclear palsy

Most Recent Events

  • 27 Mar 2015 Preclinical trials in Multiple system atrophy in USA (unspecified route)
  • 16 Jul 2014 Preclinical trials in Progressive supranuclear palsy in USA (unspecified route)
  • 21 Dec 2011 ProteoTech and GlaxoSmithKline (China) enter into a collaboration agreement to develop ProteoTech's small molecule alpha-synuclein programme for the treatment of Parkinson's disease and other synucleinopathies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top